Last Updated: November 8, 2026

Details for Patent: 8,211,880

Name: Drug Patent Intelligence for US Patent 8211880
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

Which drugs does patent 8,211,880 protect, and when does it expire?

Patent 8,211,880 protects TRIESENCE and is included in one NDA.

This patent has twenty-five patent family members in twenty-one countries.

Summary for Patent: 8,211,880

Title:	Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Abstract:	Triamcinolone acetonide suspension compositions are disclosed. The suspension compositions have a relatively low viscosity and are easy to extrude through a 27- or 30-guage needle but are highly flocculated and easily redispersed. The compositions are particularly suitable for intravitreal injection.
Inventor(s):	Bhagwati P. Kabra, Ruma Sarkar
Assignee:	Harrow IP LLC
Application Number:	US13/352,009
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 8,211,880

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Harrow Eye	TRIESENCE	triamcinolone acetonide	INJECTABLE;INTRAVITREAL	022048-001	Nov 29, 2007		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				VISUALIZATION DURING VITRECTOMY PROCEDURES	⤷ Start Trial
Harrow Eye	TRIESENCE	triamcinolone acetonide	INJECTABLE;INTRAVITREAL	022048-001	Nov 29, 2007		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				TREATMENT OF OPHTHALMIC DISORDERS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,211,880

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	070824	⤷ Start Trial
Australia	2009223649	⤷ Start Trial
Brazil	PI0909630	⤷ Start Trial
Canada	2717605	⤷ Start Trial
Chile	2009000573	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.